Coronavirus Disease 2019 (COVID-19) Vaccines: A Concise Review

Overview

Journal Oral Dis

Specialty Dentistry

Date 2021 May 15

PMID 33991381

Citations 23

Authors

Lakshman Perera Samaranayake

Chaminda Jayampath Seneviratne

Kausar Sadia Fakhruddin

Affiliations

Soon will be listed here.

Abstract

The development of a successful vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the agent of coronavirus disease 2019 (COVID-19), in an unmatched period of ten months, is a tribute to human ingenuity in the face of a vicious pandemic. A return to pre-pandemic "normalcy" depends on the successful delivery of the vaccine to a majority (~70%) so as to develop herd immunity critical to arrest the community spread of infection. Vaccination against COVID-19 is particularly important for dentistry as the dental team works in an environment replete with aerosol-generating procedures (AGP) that facilitate virus spread. Hence, a COVID-19 vaccine is likely to be an obligatory requirement for the dental practice, and the latest addition to the extensive list of vaccines required for dental professionals for the safe delivery of dental care. Here, we review the currently available major candidate vaccines against SARS-CoV-2 and their benefits and risks. These include the vaccines developed on next-generation platforms (mRNA, DNA, and viral vector vaccines), and the classic platforms (the live-attenuated virus, and the protein subunit vaccines) The review concludes with a summary of impending issues and challenges facing the provision of COVID-19 vaccines for all stakeholders in dentistry.

Citing Articles

COVID-19 vaccines: current and future challenges.

Mohammadi D, Ghasemi M, Manouchehrian N, Zafarmand M, Akbari M, Boroumand A Front Pharmacol. 2024; 15:1434181.

PMID: 39568586 PMC: 11576167. DOI: 10.3389/fphar.2024.1434181.

Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4,....

Bai S, Zhou S, Zhang J, Chen W, Lv M, Wang J Front Immunol. 2024; 15:1437267.

PMID: 39229259 PMC: 11368774. DOI: 10.3389/fimmu.2024.1437267.

Vaccination is the most effective and best way to avoid the disease of COVID-19.

Lotfi H, Mazar M, Ei N, Fahim M, Yazdi N Immun Inflamm Dis. 2023; 11(8):e946.

PMID: 37647441 PMC: 10408370. DOI: 10.1002/iid3.946.

Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models.

Park S, Jang M, Lim K, Seo J, Im W, Han K Arch Toxicol. 2023; 97(9):2429-2440.

PMID: 37491472 DOI: 10.1007/s00204-023-03549-6.

T-Cell Immunity in COVID-19-Recovered Individuals and Individuals Vaccinated with the Combined Vector Vaccine Gam-COVID-Vac.

Krechetov S, Vtorushina V, Inviyaeva E, Gorodnova E, Kolesnik S, Kudlay D Int J Mol Sci. 2023; 24(3).

PMID: 36768254 PMC: 9916700. DOI: 10.3390/ijms24031930.

References

Izzetti R, Gennai S, Nisi M, Barone A, Giuca M, Gabriele M . A perspective on dental activity during COVID-19: The Italian survey. Oral Dis. 2020; 27 Suppl 3:694-702. PMC: 7436518. DOI: 10.1111/odi.13606. View

Kumar R, Qureshi H, Deshpande S, Bhattacharya J . Broadly neutralizing antibodies in HIV-1 treatment and prevention. Ther Adv Vaccines Immunother. 2018; 6(4):61-68. PMC: 6187420. DOI: 10.1177/2515135518800689. View

Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S . The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7(3):226-36. PMC: 2750777. DOI: 10.1038/nrmicro2090. View

Clementini M, Raspini M, Barbato L, Bernardelli F, Braga G, Di Gioia C . Aerosol transmission for SARS-CoV-2 in the dental practice. A review by SIdP Covid-19 task-force. Oral Dis. 2020; 28 Suppl 1:852-857. DOI: 10.1111/odi.13649. View

Schlake T, Thess A, Fotin-Mleczek M, Kallen K . Developing mRNA-vaccine technologies. RNA Biol. 2012; 9(11):1319-30. PMC: 3597572. DOI: 10.4161/rna.22269. View

Logunov D, Dolzhikova I, Zubkova O, Tukhvatullin A, Shcheblyakov D, Dzharullaeva A . Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255):887-897. PMC: 7471804. DOI: 10.1016/S0140-6736(20)31866-3. View

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S . Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020; 383(24):2320-2332. PMC: 7494251. DOI: 10.1056/NEJMoa2026920. View

Speiser D, Bachmann M . COVID-19: Mechanisms of Vaccination and Immunity. Vaccines (Basel). 2020; 8(3). PMC: 7564472. DOI: 10.3390/vaccines8030404. View

Rauch S, Jasny E, Schmidt K, Petsch B . New Vaccine Technologies to Combat Outbreak Situations. Front Immunol. 2018; 9:1963. PMC: 6156540. DOI: 10.3389/fimmu.2018.01963. View

10.

Liu M . A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019; 7(2). PMC: 6631684. DOI: 10.3390/vaccines7020037. View

11.

Volgenant C, Persoon I, de Ruijter R, de Soet J . Infection control in dental health care during and after the SARS-CoV-2 outbreak. Oral Dis. 2020; 27 Suppl 3:674-683. PMC: 7272817. DOI: 10.1111/odi.13408. View

12.

Li D, Samaranayake L, Leung Y, Neelakantan P . Facial protection in the era of COVID-19: A narrative review. Oral Dis. 2020; 27 Suppl 3:665-673. PMC: 7300840. DOI: 10.1111/odi.13460. View

13.

Schmaljohn A . Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts. Curr HIV Res. 2013; 11(5):345-53. DOI: 10.2174/1570162x113116660057. View

14.

Kim D, Rowland-Jones S, Gea-Mallorqui E . Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Front Immunol. 2020; 11:571481. PMC: 7756008. DOI: 10.3389/fimmu.2020.571481. View

15.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

16.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

17.

Grigoryan L, Pulendran B . The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020; 50:101422. PMC: 7670910. DOI: 10.1016/j.smim.2020.101422. View

18.

Funk C, Laferriere C, Ardakani A . A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front Pharmacol. 2020; 11:937. PMC: 7317023. DOI: 10.3389/fphar.2020.00937. View

19.

Kohl K, Marcy S, Blum M, Jones M, Dagan R, Hansen J . Fever after immunization: current concepts and improved future scientific understanding. Clin Infect Dis. 2004; 39(3):389-94. DOI: 10.1086/422454. View

20.

Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q . Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines (Basel). 2020; 8(2). PMC: 7349596. DOI: 10.3390/vaccines8020153. View